Clinical trial · Interventional
Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer
NCT04319263CI-TRIAL-00044281completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective study aimed at assessment of different patterns (morphological and pathological) of tumor recurrence found at first evaluation after BCG induction therapy (3 months cystoscopy) for intermediate and high-risk NMIBC and its prognostic implications at a tertiary referral center.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| induction regimen of intravesical BCG | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- intermediate and high risk non muscle invasive bladder cancer
- interventionNames
- Drug: induction regimen of intravesical BCG
Primary outcomes (2)
- measure
- one year Recurrence rate
- timeFrame
- one year
- description
- recurrence rate at 1 year after induction BCG
- measure
- one year progression rate
- timeFrame
- one year
- description
- progression rate at 1 year after induction BCG
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients for who complete TURBT, was carried out * Intermediate and high risk NMIBC. * Patients who received full induction BCG regimen (6 weekly doses). * Patients completed at least 12 months follow up after 3 months cystoscopy. Exclusion Criteria: * Patients who received incomplete induction BCG regimen (less than 6 weekly doses) * Patients with incomplete (less than 12 months) follow up.
References
Publications (0)
Data not yet available
No reference posted for this study.